AllDocs -> cancers

1 DIAGNOSTIC IMAGING IN NEUROBLASTOMA Hans Ringertz, M.D., Ph.D. INTRODUCTION Neuroblastoma is a biologically very special neoplasm that is unique to child- hood. As can be seen from Table 1 it is the fourth most common paediatric malignancy in the Nordic countries and constitutes around 6% of all malignancies in children. Neoplasm in patients below 16 years of age in the Nordic countries during the years 1985 and 2001 in order of frequency No. of new cases % 1 Leukaemia 3249 34 2 Central nervous system and intracranial and intraspinal neoplasm 2596 27 3 Lymphomas and other reticuloendothelial neoplasm 1116 11 4 Sympathetic nervous system tumours 595 6 5 Renal tumours 556 6 6 Soft tissue sarcomas 540 5 7 Malignant bone tumours 297 3 8 Germ-cell, trophoblastic ...

PEDIATRIC ONCOLOGY GROUP Neuroblastoma Off Study Summary/Relapse Report NAME: __ HOSPITAL #: __ Last, First, M.I. TREATING PHYSICIAN: INSTITUTION: _ Form Key POG # Study # Office Disease Type: Accession # N O 1 0 (1-4) (5-10) (11-14) 1 (15) 3 (16) (17-20) Date On Therapy: _/_/_ Date Off Therapy: _/_/_ Basis of Assessment of Best Response Date of Specify Site of Response Response* Best Response Physical Exam _ _/_/_ CT or NMR _ _/_/_ Other imaging _ _/_/_ Lab _ _/_/_ Surgery _ _/_/_ Aspirate/biopsy _ _/_/_ Other _ _/_/_ Subjective _ _/_/_ *Use these codes for assessment of best response: ...

Detection of Amplification in Neuroblastoma Using Polymerase Chain Reaction and Its Impact on Survival A P RATAP , S S INHA , DK G UPTA Molecular biology has revolutionized the medicine and added a new dimension to our knowledge of disease processes, especially in the field of oncology. Proto oncogenes are proteins normally present in the genome and they may be converted to oncogenes by mutations, rearrangements, translocation and deletion. One such protooncogene is the N-myc proto-oncogene seen in neuroblastoma . Amplification of the N-myc oncogene identifies a group of patients who have a poor prognosis. At present, it is generally agreed that the amplification of N-myc is still the most important prognostic factor to be investigated in every patient with neuroblastoma because of it’s reliability as a prognostic indicator. There are many conventional ...

I80 EPIDEMIOLOGY IN THE GERMAN NEUROBLASTOMA SCREENING PROJECT C. Spix, Dt. Kinderkrebsregister, Joh.Gutenberg Universität (Mainz) In Germany Neuroblastoma is the most frequent extracranial solid childhood tumor. Its properties made it seem an ideal candidate for screening. The German childhood cancer registry was involved in the project as epidemiological consultant and to ensure ascertainment of cases and deaths. A complete registry, which determines the incidence, age at diagnosis, stage distribution, and mortality in all relevant groups (control area and study area, participants and non participants) independently of the study and beyond the field phase of the study is an optimal basis for the evaluation of a screening study. Ascertainment was achieved by regular stochastic record linkage of encrypted personal identifier data from all 1.5 million study participants with the registry data at the ...

Last Revised: 3/5/2003 UM Cancer Center Patient Education Document #0007 Mar03 Ed. Online version: http://www.cancer.med.umich.edu/learn/percpathways.htm University of Michigan Comprehensive Cancer Center Patient Education Resource Center (PERC) INFORMATION GUIDE Childhood Cancer: Neuroblastoma The purpose of this information guide is to help parents of children newly diagnosed with Neuroblastoma find sources of information and support. This list is not meant to be comprehensive, but rather to provide starting points for information seeking. The materials can be found at the Patient Education Resource Center at the University of Michigan Comprehensive Cancer Center in room B1-361. Article Available in the Patient Education Resource Center level B1 room 361 Reynolds, Patrick C. Treating High-Risk Neuroblastoma at the ...

85 Budget: Vol. I, page 153 Specific Aims Define biologic features which correlate with pathogenesis and progression Improve survival by overcoming tumor resistance Improve health-related outcome 3 Major Accomplishments Improved risk stratification with reduction of therapy in lower-risk patients and intensification in high-risk. Demonstration of a significant advantage of purged ABMT compared to chemotherapy in a randomized trial, as well as improvement in survival for stage 4 >1 year of age. Implementation of novel biological therapies with demonstration of a significant benefit of 13-cis-retinoic acid for minimal residual disease in a randomized trial Neuroblastoma Risk Groups Survival by Stage, Age, Ferritin, Pathology, MYCN CCG-3891: EFS ABMT vs Chemotherapy (as randomized) P=0.045 ...

39 Budget: Vol. I, page 155 Overall Aims Perform tests required for CCG therapeutic studies. Perform and facilitate laboratory - clinical correlative research dealing with biology, risk assessment, and therapy. Research Accomplishments MYCN and histopathology Incorporation into clinical management Confirmation of prognostic importance Identification of new subgroups Immunocytology Confirm efficacy of ex vivo purging of marrow Early identification of poor responders Biology, risk assessment, therapy Neurotrophins and receptors Molecular genetics: CGH, LOH Telomerase Metastases Cell lines: models for developing new therapy Required Tests Hypothesis 1. Risk factor analysis at diagnosis will define relatively homogenous groups for selecting therapy and for evaluating ...

POG/CCG Neuroblastoma Pathology Check List NAME: _ HOSPITAL #: __ Last, First, M.I. PRINCIPAL INVESTIGATOR: _ INSTITUTION: _ N C 1 0 (1-4) POG # Study # Office Disease Type Accession # (5-10) (11-14) 1 (15) 3 (16) (17-20) SURGICAL PATHOLOGY NUMBER: _ PATHOLOGIST: Directions: • POG INSTITUTIONS: Submit one copy of this form and the institutional pathology report to the Neuroblastoma Pathology Coordinator and two copies to the POG Statistical Office as specified in protocol section 9.0. CCG INSTITUTIONS: Send one copy to the CCG Operations office and one copy to the Biopathology Center. • POG INSTITUTIONS: A copy of the patient identification form and prestudy form should be sent to the Neuroblastoma Pathology Coordinator with ...